Insmed CEO on its Arikayce drug after shares surge on trial results [CNBC]
Insmed Incorporated (INSM)
Last insmed incorporated earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: CNBC
ICNBC's “Fast Money” team is joined by Insmed CEO Will Lewis to discuss the biotechnology company's outlook as its stock traded higher after positive trial results for its Arikayce drug.
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed Incorporated news events
Weekly update
A roundup of the hottest topics
INSM
News
- Insmed Incorporated (INSM) Shareholder/Analyst Call Transcript [Seeking Alpha]Seeking Alpha
- Insmed ENCORE Phase 3 Trial Hits Primary Endpoint; ARIKAYCE Drives Strong MAC Culture Conversion Gains [Yahoo! Finance]Yahoo! Finance
- Insmed shares rise on positive late-stage trial results for lung disease therapy [Yahoo! Finance]Yahoo! Finance
- Insmed (INSM) had its price target lowered by Wells Fargo & Company from $208.00 to $175.00. They now have an "overweight" rating on the stock.MarketBeat
- S&P 500 Futures Rise in Premarket Trading; Insmed, Mobileye Global Lead [Barron's]Barrons
INSM
Earnings
- 2/19/26 - Miss
INSM
Sec Filings
- 3/23/26 - Form 8-K
- 3/20/26 - Form 4
- 3/19/26 - Form 144
- INSM's page on the SEC website